2 Anti-remodeling agents produce similar reductions in vertebral fracture risk despite large 3 differences in BMD changes suggesting the mechanism of fracture risk reduction may 4 differ among these agents. Forty-eight intact (non-ovariectomized) skeletally mature 5 female beagle dogs were treated orally for 12 months with clinically-relevant doses of 6 risedronate (RIS, 0.10 mg/kg/day), alendronate (ALN, 0.2 mg/kg/day), raloxifene (RAL, 7 0.50 mg/kg/day), or saline (VEH, 1 ml/kg/day). After sacrifice, the following 8 measurements were made on vertebral bone: areal (aBMD) and volumetric (vBMD) 9 bone mineral densities, tissue mineralization by ash content, static and dynamic 10 histomorphometric parameters, microdamage, and extrinsic and intrinsic measures of 11 biomechanical strength, stiffness and energy to fracture. At these doses, RAL 12 suppressed bone turnover (-20%) significantly less than the bisphosphonates (-66 and -13 71%), and did not produce significant differences in aBMD, vBMD, BV/TV or percent 14 ash compared to VEH-treated animals. Microdamage accumulation in RAL-treated 15 animals was not significantly different than VEH; both RIS and ALN had significantly 16 higher crack surface density compared to VEH. Stiffness was significantly higher than 17 VEH in all treatment groups. Ultimate load divided by aBMD, a measure of strength 18 independent of BMD, was significantly higher only in RAL-treated animals compared to 19 VEH (+16%, p = 0.015). Based on these data, we conclude that raloxifene produces 20 improvements in bone mechanical properties in ways that do not involve increases in 21 BMD. 22 23
1 Introduction 2 Contributions to vertebral fracture risk reduction by factors other than bone mineral 3 density (BMD) are suggested by data showing that anti-remodeling therapies reduce 4 vertebral fracture risk by roughly the same degree (33-49% after the first 3 years of 5 treatment) even though there is as much as a six-fold difference in the increase in spine 6 BMD [1] [2] [3] [4] [5] [6] [7] . In addition, the risk of fracture to either the forearm [8] or the hip [9, 10] 7 increases with age even at equivalent bone mineral density. At the hip, for instance, the 8 ten year probability of fracture for a woman with a T-score of -2 is about 4-fold greater at 9 the age of 80 than at the age of 50 [9] . These findings, both from non-treated individuals 10 and from those on therapy, demonstrate that bone strength and fracture risk are 11 determined by more than areal bone mineral density (aBMD).
12
Raloxifene, a selective estrogen receptor modulator (SERM), suppresses bone 13 turnover and increases BMD by about half as much as the bisphosphonates (alendronate, 14 risedronate, zoledronate) but reduces vertebral fracture risk by roughly the same degree. 19 by bisphosphonates [12] [13] [14] . Together these data suggest some fundamental differences 20 in the way these two classes of anti-remodeling agents reduce vertebral fracture risk.
21
The goal of the current study was to determine if clinically-relevant doses of raloxifene 22 alter properties of canine vertebral bone in ways that differ from the bisphosphonates. 23 22 hydroxypropyl--cyclodextrin made with distilled water and administered orally with a 1 syringe. All drugs were administered in equivalent volumes (1 ml/kg/day) each morning 2 after an overnight fast and at least 2 hours prior to feeding.
3
Prior to necropsy, animals were injected with calcein (0.20 mL/kg, IV) using a 2-12-4 2-5 labeling schedule (9 animals per group) or a 2-5-2-5 (3 animals per group). The 5 shorter interlabel duration was due to a scheduling error. Animals were euthanized by 6 intravenous administration of sodium pentobarbital (0.22mg/kg Beuthanasia-D Special).
7 After death, thoracic and lumbar vertebrae were dissected and saved for analyses. The 8 ninth thoracic and fourth lumbar vertebrae were separately wrapped in saline-soaked 9 gauze and frozen (-20ºC). Second and third lumbar vertebrae were fixed in 10% neutral 10 buffered formalin. ) was cut from the mid-cranial 8 metaphysis using a band saw (Marmed Inc.) while under constant irrigation. Trabecular 9 bone specimens were dried using acetone/anhydrous ether and weighed daily until mass 10 was stabilized for two consecutive days (dry weight). Bones were ashed at 800ºC for 12 11 hours using a 1400 Thermolyne oven (Barnstead). Ashed specimens were allowed to 12 cool and then weighed (ash weight). Percent ash was calculated as ash weight/dry weight 13 * 100.
14 Histology (Static, dynamic, and microdamage) 6 Differences among treatment groups were evaluated using a one-way analysis of variance 7 (ANOVA). When a significant overall F value (p < 0.05) was present, differences 8 between individual group means were tested using Fisher's protected least-significant 9 difference (PLSD) post-hoc test. For all tests, p < 0.05 was considered significant. All 10 data are presented as mean ± standard error. (Tables 1 and 2 ). Compared to 1 VEH, neither percent ash nor bone volume were significantly different with RAL and in 2 the RIS dogs only percent ash was significantly higher (Table 2) .
3 Even with a relatively low level of remodeling suppression, RAL-treated 4 animals tended to have higher crack surface density (Cr.S.Dn) (2-fold higher vs VEH; p = 5 0.14). Cr.S.Dn was significantly higher than VEH in both RIS (+2.9-fold) and ALN 6 (+3.7-fold) groups; ALN-treated animals had significantly higher Cr.S.Dn compared to 7 RAL ( Figure 1B , Table 3 ). The non-significantly higher Cr.S.Dn with RAL was Table 3 ).
11
Stiffness was significantly higher in all groups compared to VEH while there was 12 no significant difference among groups for ultimate load or energy to ultimate load 13 (Table 4) . Normalization of ultimate load by aBMD, a measure of strength independent 14 of bone density, revealed a significant increase in RAL-treated animals (+16%; p= 0.015) 15 compared to VEH and ALN ( Figure 1D ). There was no significant difference in 16 UL/aBMD for either ALN-or RIS-treated animals compared to VEH. Vertebral 17 toughness in ALN-treated dogs was significantly less than in RAL-treated dogs (-24%, p 18 = 0.0007) and tended to be less than in VEH-treated dogs (-17%, p = 0.057) ( Figure 1C ).
19 There was no significant difference among groups for other estimated material properties 20 (ultimate stress or apparent modulus).
Discussion
22 Although routinely used as a surrogate of fracture risk, it is well accepted that bone 23 density accounts for only a portion of bone strength [11] [12] [13] [14] . In this study we attempted 1 to separate out the effects of these density-dependent parameters on vertebral bone 2 strength. We found that raloxifene-treated animals had significantly higher vertebral 3 strength (ultimate load) per unit aBMD compared to both vehicle-and alendronate-4 treated animals. This is surprising in light of the fact that raloxifene treatment suppressed 5 turnover and increased BMD less than the bisphosphonates. These observations are 6 relevant as vertebral fracture risk reduction is often estimated based on changes in bone 7 turnover rate or BMD following treatment, and suggests that raloxifene provides 8 enhanced strength independent of bone volume or mineralization of the matrix.
9
Bone strength is determined by multiple factors. At the material level, bone 10 strength, stiffness, and energy absorption are influenced by mineral, collagen, and 11 microdamage. Raloxifene-treated animals did not differ significantly from either 12 bisphosphonate-treated group with respect to mineralization (percent ash). Microdamage 13 accumulation (Cr.S.Dn) was significantly higher in raloxifene-treated animals compared 14 to vehicle, and lower than alendronate-treated animals. However, mean crack length was 15 significantly higher with raloxifene treatment compared to all other groups. Despite 16 these differences, select mechanical properties of raloxifene-treated animals were 17 significantly higher compared to alendronate (both toughness and UL/aBMD) and vehicle 18 (UL/aBMD). Given these differences, we suggest that bisphosphonates and raloxifene 19 may differentially alter the collagen component of bone tissue.
20
Estrogen and estrogen-like compounds are known to have an effect on collagen. 
19
These results should be considered within the context of the various limitations of 20 the current study. We used intact, non-ovariectomized beagle dogs and therefore it is 21 unclear if similar changes with raloxifene-treatment would occur in the absence of 22 estrogen. Additionally, for reasons unrelated to this study, serum analyses from three of 23 the raloxifene-treated dogs were conducted after 7 months of treatment and revealed the 13 1 serum concentration of raloxifene was approximately ½ of what was predicted from the 2 original dosing calculations. However, these levels were still within the range of levels 3 quantified in post-menopausal women receiving the 60 mg/day dose of raloxifene (Lilly 4 data on file). Therefore we are confident that the changes with raloxifene compared to 5 vehicle-treated animals represent changes that are clinically-relevant. As blood was not 6 saved from bisphosphonate dogs we were not able to assess the serum concentration of 7 these agents. So although the a priori dosing levels were all chosen to be equivalent to 8 the clinical doses used for post-menopausal osteoporosis, we cannot exclude the 9 possibility that differences between the bisphosphoantes and raloxifene treatments were 10 due to these dosing discrepancies.
11
In conclusion, we show raloxifene significantly improves vertebral bone strength 12 independent of bone mineral density, and that this is a fundamentally different 13 mechanism than occurs with either risedronate or alendronate. 14 
